Found: 10
Select item for more details and to access through your institution.
Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0234-4
- By:
- Publication type:
- Article
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Myelofibrosis in 2019: moving beyond JAK2 inhibition.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0236-2
- By:
- Publication type:
- Article
Oprozomib in patients with newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0232-6
- By:
- Publication type:
- Article
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0230-8
- By:
- Publication type:
- Article
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0233-5
- By:
- Publication type:
- Article
Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0228-2
- By:
- Publication type:
- Article
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy.
- Published in:
- 2019
- By:
- Publication type:
- Letter